A Phase 2 Trial Of The Bruton Tyrosine Kinase Degrader BGB-16673 In Combination With BCL-2 Inhibitor Sonrotoclax For Patients With Treatment-Naive Chronic Lymphocytic Leukemia (CLL)
Clinical trial NCT07508995 · NOT_YET_RECRUITING
Trial details
- NCT number
- NCT07508995
- Sponsor
- M.D. Anderson Cancer Center
- Status
- NOT_YET_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2026-09-01
- Primary completion
- 2031-07-01
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.